Mayne Pharma Stock Price, News & Analysis

MYPHY OTC

Company Description

Mayne Pharma (OTC: MYPHY) is a publicly traded medicinal and botanical manufacturing company in the Manufacturing sector.

This page provides a comprehensive overview of MYPHY stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart

$—

0.00%

0.00

Last updated:

Performance 1 year

$0.0

Market Cap

0.0

Shares outstanding

Latest News

View All

April 7, 2023

—

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

earnings

February 27, 2023

—

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio

acquisition

August 9, 2022

—

Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity

acquisition

August 2, 2022

—

NEXTSTELLIS® oral contraceptive has been nominated for the 2022 prix galien usa award for best pharmaceutical agent

July 29, 2022

—

MAYNE PHARMA AND GOODRX ANNOUNCE NEW INITIATIVE TO INCREASE AWARENESS OF NEXTSTELLIS® AND EXPAND ACCESS TO BIRTH CONTROL

September 21, 2021

—

FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis

fda approval

Mayne Pharma has 7 recent news articles. Key topics include earnings, acquisition, fda approval. View all MYPHY news →

SEC Filings

View All

No SEC filings available for MYPHY.

Financial Highlights

View Full Financials

—

Revenue (TTM)

—

Net Income (TTM)

—

Diluted EPS (TTM)

—

Operating Cash Flow

—

Net Profit Margin

—

Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

MYPHY Company Profile & Sector Positioning

Mayne Pharma (MYPHY) operates in the Medicinal and Botanical Manufacturing industry within the broader Manufacturing sector and is listed on the OTC.